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Gregory L. Moneta, MD, Section EditorAcute Infections and Venous Thromboembolism
Schmidt N, Horvath-Puho E, Thomsen RW, et al. J Intern Med 2012; 271:
608-618
Conclusion: Infection is a risk factor for venous thromboembolism
(VTE).
Summary: Rates of acute infections and acute venous thromboembo-
lism (VTE) are both high; therefore, any relationship between infection and
VTE has potential major clinical importance. Evidence is emerging of
a possible relationship between deep venous thrombosis, pulmonary embo-
lism, and acute infection (Smeeth L et al, Lancet 2006;367:1075-9; and
Clayton TS, Int J Epidemiol 2011;40:819-27). Studies to date, however,
have not examined the magnitude and duration of the potential increase
of VTE risk associated with hospital-acquired or community-acquired infec-
tions. The authors examined whether patients with hospital-diagnosed or
community-treated infection were at increased risk of VTE. This was a pop-
ulation-based, case-controlled study in northern Denmark encompassing
a population of 1.8 million. Data were obtained from medical databases.
All patients with a ﬁrst hospital-diagnosed VTE during the period 1999
to 2009 (n ¼ 15,009) were included. For each VTE case, 10 controls
from the general population were selected and matched for age, sex, and
county of residence (n ¼ 150,074). All hospital-diagnosed infections and
community prescriptions for antibiotics 1 year predating VTE were identi-
ﬁed. Odds ratios from a conditional logistic regression model were used
to estimate incident rate ratios (IRRs) of VTE within different time intervals
of the ﬁrst year after infection while controlling for compounding variables.
The authors found urinary tract, skin, intra-abdominal, respiratory, and
bacterial infections diagnosed in the hospital or treated in the community
were associated with a twofold or more increased VTE risk. VTE risk was
strongest within the ﬁrst 2 weeks after infection and then gradually declined.
Compared with individuals without infection during the year before VTE,
the IRR (95% conﬁdence interval) for VTE within the ﬁrst 3 months after
infection was 12.5 (11.3-13.9) for patients with hospital-diagnosed infec-
tion and 4.0 (3.8-4.1) for patients treated with antibiotics in the community
setting. IRRs (95% conﬁdence interval) were decreased after adjustment for
VTE risk factors to 3.3 (2.9-3.8) for hospital-acquired infection and to
2.6 (2.5-2.8) for community-acquired infections treated with antibiotics.
Associations were similar for unprovoked VTE, deep venous thrombosis,
and pulmonary embolism individually.
Comment: Infection is clearly emerging as a risk factor for VTE. The
primary contribution of this report is its suggestion that this increased risk of
VTE induced by infection is greatest within the ﬁrst 2 weeks after infection
onset. It follows there may be clinical circumstances in which patients with
acute infections, particularly those with other signiﬁcant VTE risk factors,
should be considered for VTE prophylaxis, at least for the ﬁrst month after
the onset of infection. A great deal of additional work remains to be per-
formed to determine precisely what types of infections, what severity of
infection, and in what particular patient subgroups such a policy of
enhanced prophylaxis could be both clinically effective and cost effective.Association of Mild to Moderate Chronic Kidney Disease With Venous
Thromboembolism Pooled Analysis of Five Prospective General
Population Cohorts
Mahmoodi BK, Ganesvoort RT, Naess IA, et al. Circulation 2012;126:
1964-71.
Conclusion: Estimated glomerular ﬁltration rate (eGFR) and
albumin-to-creatinine ratio (ACR) are both independently associated with
an increased risk of venous thromboembolism (VTE) in the general popu-
lation. This risk even holds across eGFR and ACR levels within normal
reference ranges.
Summary: In up to 50% of patients with VTE there are no known
VTE risk factors present (White RH, Circulation 2003;107:I4-8). However,
nephrotic syndrome and overt proteinuria are known risk factors for VTE
(Mahmoodi BK et al, Circulation 2008;117:224-30). This may reﬂect
that even mild to moderate chronic kidney disease (CKD) can be associated
with a procoagulant state (Dubin R, BMC Nephrol 2011;12:3). Because
there is a high prevalence of CKD in the general adult population
(10%-16%) and high numbers of VTE events yearly, the authors felt an in-600depth analysis of the association of CKDwith VTE was warranted. This study
pooled individual participant data from ﬁve community-based cohorts (three
from Europe and two from the United States). The European studies
included the second Nord-Trondelag Health Study, Prevention of Renal
and Vascular End-stage Disease Study, and the Tromso study. The United
States studies included the Atherosclerosis Risk in Communities (ARIC)
study and the Cardiovascular Health Study. Associations were determined
among eGFR, albuminuria, and CKD with objectively veriﬁed VTE.
Adjusted hazard ratios for VTE were estimated using categoric and contin-
uous spline models ﬁt by using Cox regression with shared-frailty or
random-effect meta-analysis. There were 1178 VTE events recorded during
599,453 person-years of follow-up. Relative to eGFR 100 mL/min/
1.73 m2, hazard ratios (95% conﬁdence interval) for VTE were 1.29
(1.04-1.59) for eGFR 75, 1.31 (1.00-1.71) for eGFR 60, 1.82 (1.27-
2.60) for eGFR 45, and 1.95 (1.26-3.01) for eGFR at 30 mL/min/
1.73 m2. A comparison with an ACR of 5 mg/g, found hazards ratios for
VTE were 1.34 (1.04-1.72) for ACR at 30, 1.60 (1.08-2.36) for ACR at
300, and 1.92 (1.19-3.08) for ACR at 1000mg/g. No interaction was found
between clinical categories of eGFR and ACR (P¼ .20). The adjusted hazard
ratio for CKD, deﬁned as eGFR <60 mL/min/1.73 m2 or albuminuria
$30 mg/g vs no CKD was 1.54 (1.15-2.06). Associations remained consis-
tent in subgroups with respect to sex, age, and comorbidities as well as
provoked vs unprovoked VTE.
Comment: Clearly, CKD and VTE are both common. This study
suggests, on a population basis, that even a small amount of CKD may
predispose to VTE. The authors note that the effect size of the association
may limit individual level implications. However, risk factors for VTE
frequently act in what is essentially an exponential fashion. Therefore,
even a small individually isolated effect of CKD, when combined with other
risk factors for VTE, may prove to be clinically important. Increasing greater
appreciation of risk factors for VTE and recurrent VTE should eventually
lead to more personalized determination of levels and durations of anticoa-
gulation for VTE and more directed prophylaxis for VTE in the at-risk
patient.Clopidogrel and the Risk of Osteoporotic Fractures: A Nationwide
Cohort Study
Jorgensen NR, Grove EL, Schwarz P, et al. J Intern Med 2012;272:385-93.
Conclusion: A biphasic relationship exists between the risk of frac-
tures and use of clopidogrel, with lower doses associated with decreased
facture risk and higher doses associated with increased risk.
Summary: Clopidogrel is a thienopyridine drug. The thienopyridine
drugs irreversibly inhibit P2Y12 receptor. P2Y12 belongs to a family of
G-proteinecoupled P2 purinergic, nucleotide-activated receptors (Ralevic
V et al, Pharmacol Rev 1998;50:143-92). The P2Y12 receptor is expressed
in osteoblastic cells, providing at least one mechanism for potential thieno-
pyridine toxic effects on bone cell recruitment, proliferation, and differenti-
ation (Porto I et al, Expert Opin Investig Drgs 2009;18:1317-32). Given
the potential toxic effects of clopidogrel on bone metabolism, the authors
sought to investigate the association between clopidogrel use and the risk
of fractures. This was a nationwide cohort study in Denmark of w5.3
million people that included the 77,503 patients prescribed clopidogrel
from 1996 to 2008. Nonusers of clopidogrel were randomly selected and
matched for age and sex (n ¼ 232,510). The relative risk of any fracture
and osteoporotic fractures was calculated for each clopidogrel-treated
patient and compared with the “control” patients. Table 2 from the manu-
script demonstrates that the relative risk of any fracture or an osteoporotic
fracture, “deﬁned as a hip, spine or forearm fracture,” was reduced for indi-
viduals exposed to low doses of clopidogrel but was increased in patients
treated with higher doses of clopidogrel, even within the recommended
dose range. During follow-up, individuals with low exposure to clopidogrel
(<0.01 deﬁned daily dose) had a lower risk of fractures than nonusers of
clopidogrel.
Comment: It is actually unclear how important the P2Y12 receptor is
in bone metabolism. The mechanisms whereby clopidogrel affects bone
turnover remain largely unknown. However, newer and even more potent
antiplatelet drugs such as prasugrel and ticagrelor could conceivably have
increased greater fracture risk over that of clopidogrel. The overall contribu-
tion of patient morbidity through potentially clopidogrel-facilitated
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cardiovascular events.Ischemic Preconditioning for Prevention of Contrast Medium-Induced
Nephropathy: Randomized Pilot RenPro Trial (Renal Protection
Trial)
Er F, Nia AM, Dopp H, et al. Circulation 2012;126:296-303.
Conclusion: In patients at high risk for contrast-induced nephrop-
athy, remote ischemic preconditioning (rIPC) before contrast medium
use prevents acute kidney injury (AKI).
Summary: The main predictor of contrast-induced AKI (CI-AKI) is
a decreased estimated glomerular ﬁltration rate (eGFR) of <60 mL/min/
1.73 m2. The magnitude of decrease in eGFR correlates directly with CI-
AKI (Best PJ et al, J Am Coll Cardiol 2002;39:1113-9; and Rihal CS, Circu-
lation 2002;105:2259-64). There is currently no renal protective medicine
that reliably protects high-risk patients from CI-AKI. The authors sought
to test whether a novel prevention strategy of rIPC might help preserve
kidney function in patients undergoing contrast administration for coronary
angiography. Their study is based on extrapolation from data suggesting
rIPC can prevent renal injury during surgery for abdominal aortic aneurysm
(Ali ZA et al, Circulation 2007;116(suppl):I-98-105). In this study, patients
with impaired renal function, as deﬁned by a serum creatinine >1.4 mg/dL or
an estimated glomerular ﬁltration rate <60 mL/min/1.73 m2, who were
undergoing elective coronary angiography were randomized in a 1:1 ratio to
standard carewith or without ischemic preconditioning (n¼ 50 in each group).
The rIPC was performed with intermittent upper-arm ischemia through four
cycles of 5-minute inﬂation and 5-minute deﬂation of a blood pressure cuff.
According to the Mehran Risk Score, both study groups were at high risk for
developing CI-AKI. An increase in serum creatinine $25% or $0.5 mg/dL
above baseline at 48 hours after contrast medium exposure was the primary
end point of the study. In the study, CI-AKI occurred in 26 patients (26%),
20 (40%) in the control group, and in six (12%) in the rIPC group (odds ratio,
0.21; 95% conﬁdence interval, 0.07-0.57; P ¼ .002). This apparent protective
effect was independent of all other factors such as amount of contrast medium
and patient comorbidities. rIPC also signiﬁcantly decreased the incidence of the
composite cardiovascular end point of death, hospitalization, or hemodialysis.
The number needed to treat with rIPC to prevent one case of CI-AKI was
3.6 (95% conﬁdence interval, 2-9).
Comment: The possible beneﬁcial effects of rIPC in patients with
vascular disease have been a bit of a fringe area of research for a number
of years now. This study seems reasonably well preformed, and no major
adverse events occurred related to rIPC. However, this is a single-center
trial, and despite the dramatic P values, the sample size was rather limited.
The design of the trial is relatively simple, the number of patients potentially
available for further study is large, and the need for improved renal protec-
tion in high-risk patients undergoing contrast studies is obvious. One
certainly cannot ﬁnd fault with the authors’ conclusion that “Our ﬁndings
merit a larger trial to establish the effect of remote ischemic preconditioning
on clinical outcomes.”Prospective Study of Restless Legs Syndrome and Coronary Heart
Disease Among Women
Li Y, Walters AS, Chiuve SE, et al. Circulation 2012;126:1689-94.
Conclusion: Women with restless leg syndrome (RLS) for at least 3
years have an elevated risk of coronary heart disease (CHD).
Summary: Patients with RLS (Willis-Ekbom disease) report periodic
leg movements during sleep that may occur up 200 to 300 times per night.
Such leg movements are associated with sympathetically induced heart rate
increases and elevations in blood pressure (Montplaisir J et al, Move Disord
1997;12:61-5; and Ali NJ et al, Sleep 1991;14:163-5). In addition, patients
with RLS frequently have hypertension, depression, and obesity, all of which
may put them at increased risk of heart disease. RLS patients also report
disturbed or insufﬁcient sleep, which can also increase the risk of heart
disease (Cappuccio FP et al, Eur Heart J 2011;32:1484-92). Patients
with RLS have indeed been associated with an increased risk of CHD.
The ﬁrst report of an association of RLS with CHD was in 2001 in Swedish
men (Ulfberg J et al, Mov Disord 2001;16:1159-63). However, this obser-
vation, although conﬁrmed by other cross-sectional studies, was not
conﬁrmed by prospective evaluation in two additional studies. The prospec-
tive studies, however, did not take into account duration of RLS symptoms.
In the current study, the authors examined whether RLS was associated
with an increased risk of CHD in women who participated in the Nurses’
Health Study and took into account duration of RLS symptoms. There
were 70,977 women (mean age, 67 years) free of CHD and stroke at base-
line (2002) who were monitored until 2008. Physician-diagnosed RLS wasdetermined by questionnaire. CHD was deﬁned as myocardial infarction or
fatal CHD. Women who had RLS at the time of entry into the study (base-
line) had a higher risk of developing CHD (multivariable-adjusted hazard
ratio [HR], 1.46; 95% conﬁdence interval [CI], 0.97-2.18). Risk (HR
[95% CI]) was dependent on duration of symptoms, 0.98 (0.44-2.19) for
women with RLS for <3 years and 1.72 (1.09-2.73) for women with
RLS >3 years (P ¼ .03 for trend). Multivariable-adjusted HRs (95% CI)
of women with RLS for >3 years were 1.08 (1.07-3.01) for nonfatal
myocardial infarction and 1.49 (0.55-4.04) for fatal CHD compared with
women without RLS.
Comment: RLS is common and bothersome. Anecdotally, it is
frequently seen in patients with peripheral arterial disease (PAD). Given
the unquestioned association between CHD and PAD, one wonders if
RLS, if carefully studied in patients with PAD, would be found to also be
statistically associated with PAD, perhaps independent of CHD?Shorter Duration of Femoral-Popliteal Bypass Is Associated With
Decreased Surgical Site Infection and Shorter Hospital Length of Stay
Tze-Woei T, Kalish JA, Hamburg NM, et al. J Am Coll Surg 2012;215:
512-8.
Conclusion: In femoral-popliteal bypass performed with autogenous
vein, longer operations are associated with a higher risk of perioperative
surgical site infections and longer hospital stays.
Summary: Multiple factors inﬂuence the duration of a surgical proce-
dure. Some are patient-speciﬁc, whereas others are surgeon-speciﬁc and
system-speciﬁc. Surgeon-speciﬁc factors may include the choice of surgical
technique, surgical judgment, technical skill, and experience. Patient-
speciﬁc factors include presence of scar tissue or inﬂammation, patient
body habitus and physiologic status, and the physical quality of relevant
tissues or organs used in the reconstruction. The efﬁciency of the operating
room support staff and participation of surgical trainees in procedures are
also system-speciﬁc factors that may inﬂuence the duration of surgery.
The authors’ hypothesized shorter operative durations would be associated
with improved outcomes of femoral-popliteal bypass. They used the Amer-
ican College of Surgeon’s NSQIP Dataset from 2005 to 2009 to identify
patients who underwent a femoral-popliteal bypass as a primary operation
with autogenous vein. Operative duration quartiles (Q) were deﬁned as
Q1, 149 minutes; Q2, 150 to 192 minutes; Q3, 193 to 248 minutes;
and Q4, $249 minutes. Perioperative outcomes analyzed included hospital
length of stay, mortality, cardiopulmonary complications, and surgical site
infection. Patient-speciﬁc and system-speciﬁc variables analyzed included
age, body mass index, smoking, diabetes, end-stage renal disease, indication
for surgery, American Society of Anesthesiologist’s class, type of anesthesia,
intraoperative transfusion, nonoperative time in the operating room, and
participation of a trainee during the procedure. Multivariable regression
was used to adjust for variables. There were 2,644 femoral-popliteal bypass
procedures in this study. Patient mean age was 65.9 years, and 62% were
men. Longer operations were associated with increased perioperative
surgical site infection (Q1, 6.3%; Q2, 9.0%; Q3, 10.1%; Q4, 13.9%;
P < .001). Longer surgical durations were also associated with longer
lengths of stay (5.4 6 6.8, 6.1 6 6.7, 7.0 6 11.3, and 8.1 6 8.0 days,
respectively; P < .001). With multivariable analysis, longer operative dura-
tion remained independently associated with a higher rate of surgical site
infection and longer hospital stays. Risk of surgical site infection increased
by 50% with operative durations of $260 minutes compared with operative
times of 150 minutes.
Comment: The relevance of procedure length on patient outcomes
is controversial. Authors have found both positive correlations with com-
plications with increased procedure length (Cruse PJE et al, Arch Surg
1973;107:206-10). Others have found no association between procedure
length and patient outcomes (Scheer A et al, Dis Colon Rectum 2009;
52:1746-52). Most analyses have been of general or laparoscopic surgical
procedures. The authors here present a relatively unique analysis of surgical
duration on outcomes of vascular surgical procedures that attempted to
control for patient-speciﬁc and system-speciﬁc factors. Their conclusion is
that because they controlled for patient-speciﬁc and system-speciﬁc factors,
the length of time required for femoral-popliteal bypass is at least partly inﬂu-
enced by surgeon-speciﬁc factors such as speciﬁc surgical techniques, surgical
judgment, technical skill, and the overall pace of the operation. There was
no denying that the duration of surgery of femoral-popliteal bypass in
the authors’ data was associated with increased surgical site infection and
hospital length of stay. Therefore, it would appear that system-speciﬁc and
surgeon-speciﬁc factors that lower the duration of femoral-popliteal bypass
are reasonable targets to facilitate quality improvement.
